|Day's Range||12.90 - 12.90|
Consider AbbVie's (NYSE: ABBV) crown jewel drug, Humira, which hauled in $21.2 billion in revenue in 2022. The good news is that AbbVie knew this day would come and has been preparing. SLE is an autoimmune disease that affects multiple organs of the body.
In the last year, many AbbVie Inc. ( NYSE:ABBV ) insiders sold a substantial stake in the company which may have...
A common misconception is that you need a lot of money to invest in the stock market. Let's look at three healthcare stocks that can be purchased for $100 and have good prospects to grow over time. The stock hasn't been off to a great start this year, dipping 18%, but the odds look pretty good for the company in the near future.